Fosun Pharma USA has Preferred Access to Broader Fosun Ecosystem

FOSUN PHARMA USA INC.

- Fosun Pharma USA is part of **larger parent organization Fosun Pharma Group**
- Fosun Pharma Group has ownership in Fosun Pharma USA as well as **Henlius & Fosun-Kite**
  - Fosun Pharma USA has **preferred access to Henlius & Fosun-Kite assets** for US development consideration

Company	Asset	MoA	Indication / Clinical Stage
Henlius	HLX22	Targeting Her2 (mAb, IV)	Gastric cancer / Ph3 ready global pivotal trial
Henlius	HLX43	PD-L1-targeting ADC (mAb, IV)	Advanced, metastatic solid tumors / Ph1 in China
FOSUNKite 复星凯特生物	FKC-288	Targeting BCMA/CD19 (CART, IV)	Multiple Myeloma / IIT-PoC
FOSUNPHARMA 复星医药	FH-2001	Targeting FGFR/VEGFR (Small Molecule, Oral)	Advanced solid tumors / Ph 1b/2 in China
FOSUNPHARMA 复星医药	SAF-189	Targeting ALK/ROS1 (Small Molecule, Oral)	ALK+ NSCLC / Ph 3 in China

HLX22(HER2): Potential to Address Critical Unmet Need in HER2 Positive Gastric Cancer

FOSUN PHARMA USA INC.

Unmet need

- Gastric/gastroesophageal junction (G/GEJ) cancer represents a global healthcare challenge with **>1 million new cases** in 2020, **5th** among all cancers.
- **Poor prognosis**, with a **5-years** relative survival of only **6%.**
- Around ~20% are **HER2+** whose **prognosis** is **worse** than **HER2-** disease.

Competitive landscape

- **Safety profile favorable** to a potential **competitive drug** in development due to manageable **diarrhea issues**.
- Discussions with **top US experts** in Gastric Cancer **unanimously positive** with expressed **interest** to **participate in the Phase 3 trial.**

HLX22 strengths

- **Reduction of the risk of progression by 90% (HR = 0.1) and risk of death by 70% (HR = 0.3).**
- **Novel binding epitope on HER2** that allows combinability with the current standard of care (trastuzumab) and **synergistic clinical activity**.
- Results from a **randomized, double blinded, phase 2 trial conducted in 28 sites.**
- Data presented at **ASCO GI 2024.**
- Potential **label in Gastric Cancer** opens potential for use in **other HER2 expressing cancers** (this can be leveraged by US specific IITs down the road).

Clin. Trial Feasibility

- **Regulatory: Positive outcomes from the FDA meeting in January**, which allowed addition of IO (pembrolizumab) to the control arm **but did not require the same for the active HLX22 arm.**
- **Operational feasibility:** (i) Relatively small patient population in the US (~20% of all Gastric Cancer), Planned participation of US investigators and sites in the Global trial

Fosun Pharma USA has Preferred Access to Fosun Pharma Group Pipeline

FOSUN PHARMA USA INC.



Note: CLDT: thrombocytopenia caused by chronic liver disease

Sources: Fosun Pharma IR Deck (Jan 2024)

Fosun Pharma USA has Preferred Access to Henlius Pipeline

FOSUN PHARMA USA INC.



(1) IND approvals obtained in China/the U.S./EUUS countries/Australia, etc. Approved by the NMPA in March 2022. Business partners: KGbio/Fosun Pharma/Intas. (2) IND approvals obtained in Australia. (3) IND approvals obtained in China/Australia. (4) Business partner: Shanghai Jingze. (5) IND approvals obtained in China/the U.S.. (6) Commercialization rights obtained for Mainland China, Hong Kong, Macao and Taiwan. (7) IND approvals obtained in China/Australia/the US/Singapore/EU countries, etc. Business partner: Essex. (8) IND approvals obtained in China/EU. Business partner: Organon. (9) IND approvals obtained in China/EU/Australia. Business partner: Organon. (10) Approved in 40+ countries, including China, the UK, Germany, France and Australia, trade name registered in Europe: Zercepac®, trade name registered in Australia: Tuzucip® and Trastucip®. Business partners: Accord/ Cipla/ Jacobson/ Elea/ Eurofarma/ Abbott/KGbio. (11) The first biosimilar approved in China. Business partners: Fosun Pharma/Farma de Colombia/Eurofarma/Abbott. (12) The first rituximab approved for the indication in China. (13) Business partners: Wanbang/Getz Pharma. (14) Business partner: Eurofarma.

Source: Henlius IR Deck (2024 Annual)